| Ms Holly B Frost, CNM | |
|
100 Brickhill Ave Ste 304, South Portland, ME 04106-1999 | |
| (207) 761-4700 | |
| (207) 761-4744 |
| Full Name | Ms Holly B Frost |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 100 Brickhill Ave Ste 304, South Portland, Maine |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205047792 | NPI | - | NPPES |
| 432787099 | Medicaid | ME | |
| 30346324 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 024695 (Maine) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Holly B Frost, CNM 100 Brickhill Ave Ste 304, South Portland, ME 04106-1999 Ph: (207) 761-4700 | Ms Holly B Frost, CNM 100 Brickhill Ave Ste 304, South Portland, ME 04106-1999 Ph: (207) 761-4700 |
News Archive
Merck is pleased to announce that New Brunswick, Nova Scotia and Alberta are the first provinces in Canada to reimburse SIMPONI(golimumab) for the treatment of three different rheumatic conditions. SIMPONI, a subcutaneous anti-tumor necrosis factor therapy, is now reimbursed by the drug formularies of these three provinces for people living with moderately to severely active rheumatoid arthritis, moderately to severely active psoriatic arthritis and active ankylosing spondylitis.
A new study by researchers at Curtin University of Technology shows that eating yellow, orange and red fruits such as tomatoes, watermelon and citrus, and vegetables such as red capsicum or sweet pepper, pumpkin and spinach may reduce the risk of developing prostate cancer by up to 50 per cent.
Individuals with severe forms of COVID-19 disease can present with compromised type I interferon (IFN) responses based on their genetics, according to results published in two papers today in the journal Science.
Vaxil Bio, a leading developer of immunotherapeutic products to treat cancer and infectious diseases, reports today that its lead drug candidate, ImMucin has received orphan drug designation from the European Medicines Agency of the European Commission for the treatment of Multiple Myeloma (MM), a blood cancer.
Scientists have clarified details in understanding the beneficial function of a type of protein normally associated with prion diseases of the brain, such as bovine spongiform encephalopathy (commonly known as mad cow disease) and its human counterpart, variant Creutzfeldt-Jakob disease.
› Verified 4 days ago
Katherine Gleason Beach, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 100 Brickhill Ave, South Portland, ME 04106 Phone: 207-761-1502 Fax: 207-774-2015 |